PredictaChart by Predicta Med is an innovative medical record summary tool designed to enhance clinical efficiency and decision-making. This AI-powered solution leverages natural language processing (NLP) to extract and prioritize key information from vast volumes of clinical notes, ensuring that physicians focus on the most relevant data.

Key Features and Benefits:

Content Prioritization for Efficiency

PredictaChart creates a concise, specialty-specific view of a patient's clinical information, tailored to their conditions. This prioritization reduces the time required for chart reviews and allows physicians to concentrate on critical issues.

AI-Driven Insights

Using advanced NLP, the tool identifies vital information often buried within extensive records from multiple providers, making patient health data more accessible and actionable.

Improved Clinical Decision-Making

By highlighting urgent or relevant issues, PredictaChart supports faster, patient-specific decision-making. It empowers clinicians with better insights to address the unique needs of each patient.

Enhanced Patient Care

The tool accelerates diagnosis and treatment by streamlining access to vital information. Automated checks for inconsistencies or missing data reduce the risk of errors, contributing to more precise and effective care.

PredictaChart transforms how specialists interact with medical records, helping them save time, improve accuracy, and deliver optimal patient outcomes.

Predicta Med is transforming the care of autoimmune diseases by offering an EMR-integrated platform that accelerates diagnosis and intervention. The platform includes three core modules:

• PredictaAI: The first AI-driven solution designed for early detection and tailored intervention of autoimmune diseases, enhancing diagnostic accuracy and speed.
• PredictaChart: The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews.
• PredictaMatch: A patient eligibility assessment tool, seamlessly embedded in EMRs, providing healthcare providers with relevant treatment options based on a patient’s disease profile.

Together, these modules enable faster, more accurate care decisions, improving outcomes for patients with autoimmune diseases

• eCART is a research-based, AI-driven software as a medical device (SaMD) that utilizes a machine learning algorithm to continuously assess hospitalized patients’ risk of impending death or intensive care unit (ICU) transfer, assisting medical staff in swift and accurate recognition of patients requiring increased medical attention. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts likelihood of critical illness onset, hours before it happens.
• eCART received FDA 510(k) clearance in 2024, with clinical performance data of nearly two million hospitalizations from 21 hospitals, including an unprecedented level of real-world prospective data, to ensure consistent accuracy across geography, age, race, and top medical conditions (e.g. sepsis, COPD, heart failure). 
• Built upon more than a decade of ongoing scientific research, eCART was developed at UChicago Medicine by Dr. Dana Edelson, MD, MS and Dr. Matthew Churpek, MD, PhD and is well chronicled in published literature. The analytic and workflow have been in use in clinical practice since 2016.

At AgileMD, we are building the most advanced real-time predictive analytics and clinical pathways platform for hospitals.

To date, AgileMD tools have been used on more than 4 million patient encounters by more than 135,000 clinical users in over 250 hospitals, including some of the nation's leading academic medical centers. AgileMD's eCART clinical deterioration prediction software is FDA cleared and the first AI-powered early warning device for ward patients to go through the FDA process with real-world prospective data. 

AgileMD is backed by premier start-up partners MATTER, YCombinator, and Rock Health, and our cutting-edge analytics are built on more than decade of ongoing research at the University of Chicago. In 2021, AgileMD garnered nearly $3 million in combined federal research and development funding from the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews

Established partnerships with global experts specialists.  

Domain expertise in specialty diseases and specialty care.

Trained & validated on proprietary specialty care specific large data sets.

Seamless EMR integration.

• Continuously monitors EHR data in real time
• Stratifies hospitalized patients by risk of impending all-cause clinical deterioration and sepsis
• Notifies inpatient providers when patient may need additional assessment and management
• Recommends clinical pathways with integrated order entry

• Authorized: FDA 510(k) cleared
• Tested: Derived and validated in nearly 3 million patient encounters across 28 hospitals
• Experienced: 8+ years in clinical use; 10+ years of published academic literature on value over other early warning scores
• Accurate: High sensitiviy and specificity, meaning fewer false alarms and more efficient focus on the highest risk patients
• Integrated: Embedded cross-team workflow ensures that risk scores are not ignored and action is taken
• Benchmarked: Robust reporting, benchmarking, and implementation support drive quality improvement